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Abstract
A clinical isolate of C. freundii with reduced susceptibility to extended-spectrum b-lactams from a woman with
cystocele associated with recurrent urinary tract infection was analyzed. Susceptibility tests, double disk synergy
tests (DDST) and enzymatic activity by the agar iodometric method suggested the presence of ESBLs. Conjugation
experiments revealed the presence of a large conjugative plasmid (pLM07/20) with an exclusive FrepB replicon
type (IncF/FIB). PCR analysis and sequencing confirmed the presence of the blaCTX-M-14 gene in the pLM07/20 from
C. freundii.LM07/10. Although this is the first report of CTX-M-14 in Venezuela, we alert the medical community that
future increase of these b-lactamases in our city could be due to dissemination of plasmids into bacterial
populations.
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Background
Extended-spectrum b-lactamases (ESBLs) create signifi-
cant therapeutic problems by inactivating almost all b-
lactams except cephamycins and carbapenems. Follow-
ing the detection of the first ESBL, TEM and SHV-
derived ESBLs evolved and disseminated globally up to
the late 1990s. Since then, a new epidemiological situa-
tion lead to a predominant increase of CTX-M derived
enzymes [1]. Infections caused by ESBL-producing
Enterobacteriaceae have mostly been described as hospi-
tal-acquired, associated with health care facilities [2],
and, with increasing frequency, isolated from patients
from both extended-care facilities and community-onset
diseases [3,4]. Citrobacter freundii is an opportunistic
pathogen that can cause diarrhea, septicemia, meningi-
tis, and respiratory and urinary tract infection, especially
in high-risk groups [5]. Multidrug resistance in Citro-
bacter spp. is a growing concern all over the world, and
extended-spectrum cephalosporins are currently used to
treat infections caused by these microorganisms.
Numerous international molecular studies have also
described the occurrence of various CTX-M types in
species of Citrobacter, CTX-M-9 in the United Kingdom
[6], CTX-M-30 in Canada [7], CTX-M-3 in Korea [8],
CTX-M-2 in Japan [9], CTX-M-14 in China [10], and
CTX-M-15 in India [11]. However, the distribution of
CTX-M producers among community-onset pathogens
from South America, especially in Venezuela, remains
scarcely known. In this report, we describe a clinical iso-
late of C. freundii with reduced susceptibility to
extended-spectrum cephalosporins that produces a
CTX-M-14 type b-lactamase, from a woman with cysto-
cele and urinary infection.
Case presentation
In June 2010, a 47-year-old woman was assisted in pri-
vate consulting with a history of grade II cystocele and
recurrent urinary tract infection since December 2009.
One cephalosporin-resistant strain of Citrobacter freun-
dii LM07/10 was isolated from an urine sample. The
strain was identified using conventional biochemical
tests and confirmation was realized by API 20E system
(bioMérieux, Marcy l’Etoile, France). The patient was
treated according to the susceptibility test with i.v. mer-
openem. Also, a surgical treatment to repair the anterior
vaginal wall prolapse was suggested.
Antimicrobial susceptibility testing was determined
using the agar dilution method according to the recom-
mendations of the Clinical and Laboratory Standards
Institute (CLSI) [12]. The following antimicrobials
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cefotaxime, ceftazidime, ceftazidime plus clavulanic acid,
aztreonam, imipenem, meropenem, ciprofloxacin, genta-
micin, amikacin and tobramycin. The ESBL phenotype
was detected by the double disk (Oxoid, Basingstoke,
Hampshire, England) synergy test (DDST) according to
CLSI [12] guidelines. The quality control strains used
were Escherichia coli ATCC 25922 (negative control for
ESBL) and Enterobacter cloacae UBA-G CTX-M-9
(positive control for ESBL). b-lactamase presence in
crude extracts obtained by sonication was confirmed by
an agar iodometric method [13] with minor modifica-
tions [14] using cefotaxime as substrate.
To determine whether the resistance was transferable,
conjugation experiments using mixed broth cultures were
performed with E. coli J53 (azide
R) as recipient. Transcon-
jugants were selected on Levine agar (Britania, Buenos
Aires, Argentina) plates containing 75 μg/ml of azide and
2 μg/ml of cefotaxime. The presence of blaCTX-M genes in
the transconjugants was confirmed by DDST and PCR.
Plasmid DNA from transconjugants was extracted by the
rapid alkaline lyses method [15] and then analyzed by elec-
trophoresis on a 0.8% agarose gel and visualized by stain-
ing with ethidium bromide under UV light. Identification
of plasmids by PCR-based replicon typing was carried out
as described by Carattoli et al. [16].
Detection of antimicrobial resistance blaCTX-M and
blaCTX-M-9 genes were performed by PCR amplification
using the following primers sets [17]: CTX-M-GF- 5’ATG
TGC AGY ACC AGTA ARG TKA TGG C ‘3a n dC T X -
M-GR- 5’ CCG CTG CCG GTY TTA TCV CCB AC ‘3
for blaCTX-M; CTX-M-9F- 5’AAC ACG GAT TGA CCG
TCT TG ‘3a n dC T X - M - 9 R -5 ’ TTA CAG CCC TTC
GGC GAT ‘3f o rblaCTX-M-9. The presence of the other b-
lactamase genes was determined by previously described
primers [11]. DNA templates were prepared by suspend-
ing one or two fresh colonies in 200 μl of sterile distilled
water and heating at 95°C for 10 min. Amplification was
performed in a final volume of 25 μlc o n t a i n i n g1μMo f
each primer, 0.2 mM of dNTPs, 1.5 mM MgCl2 and 1 unit
of Taq polymerase. PCR products were visualized by elec-
trophoresis on 1% agarose gels, stained with ethidium bro-
mide (50 μg/ml) and photographed with UVP Biodoc-It
System. Amplification products were purified (Sigma PCR
C l e a n u pk i t )a n dt h e i rn u c l e otide sequencing was per-
formed with the ABI Prism 377 genetic analyzer (Applied
Biosystems, CA, USA). Nucleotide and amino acid
sequence alignments were analyzed using the Basic Local
Alignment Search Tool (BLAST) suite of programs
(http://www.ncbi.nlm.nih.gov/BLAST.cgi).
Discussion
Recurrent urinary tract infection (UTI) remains an
important public health problem in women of all ages
[ 1 8 ] .W er e p o r t e dac a s eo faw o m a nw i t hg r a d eI I
cystocele associated with recurrent UTI. This patient
had more than three microbiologically documented epi-
sodes of symptomatic UTI during the last 6 months.
Initially the patient was managed with empirical first
line antibiotic therapy (amoxicillin or cephalexin) and
later with extended-spectrum cephalosporins (ceftriax-
one or cefotaxime). Recurrent infections are of particu-
lar concern because of the repeated morbidity and
necessity for frequent administration of antibiotics with
the possible adverse consequences of selection of anti-
microbial-resistant strains.
A clinical isolate of C. freundii with reduced suscept-
ibility to extended-spectrum b-lactam was collected
from the patient urine sample. This isolate showed a
multidrug resistance phenotype including ceftriaxone,
cefotaxime, gentamicin, tobramycin and ciprofloxacin,
but was completely susceptible to carbapenems. The
DDST and enzymatic activity by the agar iodometric
method suggested the presence of ESBL, which was con-
firmed by restored susceptibility to cefotaxime in the
presence of clavulanic acid (Table 1). All resistance (or
reduced susceptibility) markers were transferable by
conjugation to recipient E. coli (J53 azide
R), except
ciprofloxacin. In this study, C. freundii harbored a plas-
mid of >150 kb with a FrepB replicon belonging to the
IncF/FIB group. The identification of a family of related
plasmids has important public health implications since
it demonstrates that broad-host range plasmids carrying
resistance to clinically relevant antibiotics can spread
worldwide among bacteria responsible of both nosoco-
mial and community-acquired infections [19].
Further DNA templates of C. freundii LM07/10, E.
coli J53-07/20 transconjugants and plasmid (pLM07/20)
were screened by PCR assays for blaTEM, blaSHV and
blaCTX-M genes. Primers specific to the blaCTX-M-9
group gave positive gene amplification (850 bp frag-
ment). Sequence analysis of the amplification product
revealed the presence of blaCTX-M-14.
ESBLs-producing Enterobacteriaceae were previously
identified in the small number of studies of venezuelan
hospital-derivated isolates [20-23]. Previous reports of
genotypes of ESBL genes from Venezuela were sporadic
a n di n v o l v e dS H V - 5a n dC T X - M - 2 ,b e i n gp a r t i c u l a r l y
common in Klebsiella pneumoniae of nosocomial origin
[20-22]. Also, the distribution of different genotypes of
ESBLs in hospital or community in Venezuela is poorly
understood. This is the first report of a CTX-M-14 b-lac-
tamase producing C. freundii in Venezuela associated with
a large conjugative plasmid with an exclusive FrepB repli-
con type (IncF/FIB) isolated from a community patient.
But previous studies indicated that others replicons of dif-
ferent incompatibility groups (IncI or IncK) can also be
involved in the dissemination of CTX-M-14 [24,25].
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producing organisms might be an emerging problem in
outpatient settings in different countries [3,26]. Few data
regarding the molecular epidemiology of CTX-M type
ESBLs-producing C. freundii isolated from patient with
community-onset infections are available [17,26].
According to the findings from this study, we may
assume the hypothesis that microorganisms with anti-
biotic resistance mechanisms can be present in patients
in the community and it is possible that healthy people
could act as a reservoir of these ESBLs as a consequence
of antibiotic use and abuse. Only through the recogni-
tion of factors associated with increasing resistance and
the study of the molecular mechanisms involved, strate-
gies can be traced and b-lactam resistance minimized.
In conclusion, this study supports the view that CTX-
M-14 producing C. freundii is an emerging pathogen in
community settings in Mérida, Venezuela, and that
increased efforts in surveillance and study of risk factors
associated with these bacteria are needed.
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